$23.35+0.13 (+0.56%)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $23.35. The stock is currently 27% below its 52-week high of $31.77, remaining 2.2% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why ARQT maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assessing recent moves in Arcutis Biotherapeutics (ARQT) Arcutis Biotherapeutics (ARQT) has drawn attention after a recent share price move, with the stock closing at US$22.86 and showing mixed performance over the past week, month, and past 3 months. See our latest analysis for Arcutis Biotherapeutics. While the latest 1-day share price return of 3.75% decline and 7-day share price return of 5.50% decline point to fading short-term momentum, the 1-year total shareholder return of 55.30%...
Arcutis Biotherapeutics now sits at the center of a fairly tight cluster of Street price targets, with several analysts coalescing around about $35 after recent model updates. Those tweaks, which include both upward and downward revisions into the mid $30s, are being tied directly to Q4 results, refreshed guidance, and evolving views on the Zoryve rollout. As you read on, you will see how these small shifts feed into the broader analyst narrative and what to watch as new data points...
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the 10 Overlooked Growth Stocks to Buy Now. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the overlooked growth stocks to buy now. On March 28, Arcutis Biotherapeutics presented new Phase 2 data from its INTEGUMENT-INFANT trial at the 2026 American Academy of Dermatology Annual Meeting. The study evaluated […]